Eli Lilly and Company (NYSE:LLY) Issues FY 2026 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 35.500-37.000 for the period, compared to the consensus earnings per share estimate of 34.390. The company issued revenue guidance of $82.0 billion-$85.0 billion, compared to the consensus revenue estimate of $81.9 billion.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 6th. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Friday, March 13th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,218.93.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $33.25 on Friday, hitting $967.85. The stock had a trading volume of 2,667,433 shares, compared to its average volume of 3,173,909. The company’s 50-day moving average is $947.05 and its two-hundred day moving average is $984.98. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The stock has a market cap of $914.44 billion, a price-to-earnings ratio of 42.20, a P/E/G ratio of 1.00 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts expect that Eli Lilly and Company will post 33.79 earnings per share for the current year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat and stronger guidance — Lilly reported a sizable revenue and EPS beat (Q1 revenue up ~56%, EPS well above estimates) and raised FY2026 revenue and EPS ranges, signaling continued demand for its GLP?1 franchise. Lilly’s Double-Beat Widens the GLP-1 Gap
• Positive Sentiment: Foundayo early uptake and product advantage — The FDA approval of Foundayo (oral GLP?1 with no food/water timing limits) and management comments that >20,000 patients have already started dosing support a durable competitive edge in convenience for obesity treatment. Foundayo approval & early uptake
• Positive Sentiment: Regulatory tailwind — The FDA proposal to exclude key GLP?1 active ingredients from bulk compounding would limit cheaper, compounded alternatives and protect branded supply/pricing. That regulatory move reduces a key near?term downside risk. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Analyst upgrades/price target increases — Multiple firms (including Goldman Sachs and Cantor Fitzgerald) raised price targets and maintained bullish ratings after the quarter, supporting further upside sentiment. Goldman Sachs raises PT
• Neutral Sentiment: Valuation and long?term upside debate — Some analysts and models argue that Lilly still has meaningful upside based on structural shifts in its business, while others say its scale already prices much of the GLP?1 story; this is driving mixed views on near?term entry points. Trefis: Path to 30% upside
• Negative Sentiment: Intensifying competition — Novo Nordisk has relaunched oral Ozempic (rebranded Rybelsus) into ~70,000 U.S. pharmacies, expanding patient access and posing direct competition to Foundayo’s uptake and pricing dynamics. Novo launches Ozempic pills
• Negative Sentiment: Pricing pressure and PBM friction — Investors remain mindful of pharmacy benefit manager negotiation pressure and margin effects; some analysts have trimmed out?year estimates citing pricing dynamics. Pricing pressure discussion

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mcguire Capital Advisors Inc. bought a new stake in Eli Lilly and Company in the fourth quarter worth $38,000. TMB Capital Partners LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $456,000. Strive Financial Group LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $1,950,000. Widmann Financial Services Inc. boosted its holdings in Eli Lilly and Company by 7.8% in the fourth quarter. Widmann Financial Services Inc. now owns 1,038 shares of the company’s stock worth $1,116,000 after purchasing an additional 75 shares in the last quarter. Finally, First Commonwealth Financial Corp PA boosted its holdings in Eli Lilly and Company by 3.1% in the fourth quarter. First Commonwealth Financial Corp PA now owns 2,078 shares of the company’s stock worth $2,233,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.